Table 2.
Multivariable Cox regression analysis of GC patients' prognosis in training, validation and combining sets.
| Variables | Training set | Validation set | Combining set | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Overall survival | ||||||
| Age (≥58 vs. < 58) | 1.26 (0.83–1.54) | 0.397 | 1.12 (0.61–1.41) | 0.665 | 1.18 (0.72–1.49) | 0.547 |
| Sex (male vs. female) | 1.17 (0.86–1.45) | 0.748 | 1.37 (0.88–1.64) | 0.339 | 1.23 (0.84–1.56) | 0.438 |
| Tumor site (proximal + middle vs. distal) | 1.13 (0.66–1.74) | 0.437 | 0.98 (0.81–1.32) | 0.933 | 1.06 (0.78–1.44) | 0.864 |
| TNM stage (III + IV vs. I + II) | 2.51 (1.29–5.39) | 0.001 | 2.36 (1.22–5.17) | 0.006 | 2.43 (1.24–5.26) | 0.004 |
| Differentiation (poor vs. well + moderate) | 1.63 (0.89–2.27) | 0.171 | 1.77 (0.92–2.89) | 0.102 | 1.68 (0.94–2.37) | 0.115 |
| Lauren classification (diffuse vs. intestinal) | 1.74 (0.97–2.53) | 0.075 | 1.69 (0.88–2.36) | 0.121 | 1.72 (0.94–2.46) | 0.107 |
| RTL (short vs. long) | 2.95 (1.31–5.53) | 0.001 | 2.46 (1.18–4.37) | 0.005 | 2.78 (1.24–4.48) | 0.003 |
| Chemotherapya (yes vs. no) | 0.41 (0.17–0.84) | 0.008 | 0.49 (0.21–0.86) | 0.012 | 0.47 (0.19–0.84) | 0.009 |
| Relapse‐free survival | ||||||
| Age (≥58 vs. <58) | 1.13 (0.86–1.36) | 0.769 | 1.09 (0.79–1.52) | 0.541 | 1.10 (0.83–1.45) | 0.494 |
| Sex (male vs. female) | 1.20 (0.73–1.98) | 0.354 | 1.25 (0.91–1.69) | 0.113 | 1.21 (0.87–1.78) | 0.215 |
| Tumor site (proximal + middle vs. distal) | 1.28 (0.76–1.87) | 0.247 | 1.15 (0.81–1.47) | 0.673 | 1.19 (0.78–1.64) | 0.345 |
| TNM stage (III + IV vs. I + II) | 2.46 (1.38–5.93) | <0.001 | 2.41 (1.28–5.48) | 0.002 | 2.45 (1.22–5.36) | 0.003 |
| Differentiation (poor vs. well + moderate) | 1.61 (0.82–2.81) | 0.178 | 1.69 (0.89–2.97) | 0.102 | 1.67 (0.87–2.86) | 0.115 |
| Lauren classification (diffuse vs. intestinal) | 1.65 (0.91–2.59) | 0.084 | 1.73 (0.98–2.88) | 0.062 | 1.69 (0.95–2.64) | 0.073 |
| RTL (short vs. long) | 2.76 (1.22–4.73) | 0.004 | 2.52 (1.21–3.98) | 0.006 | 2.64 (1.19–4.55) | 0.007 |
| Chemotherapya (yes vs. no) | 0.42 (0.20–0.91) | 0.022 | 0.51 (0.24–0.88) | 0.016 | 0.49 (0.28–0.80) | 0.017 |
Notes: RTL, relative telomere length; HR, hazard ratio; 95% CI, 95% confidence interval; TNM, tumor‐node‐metastasis.
We calculated hazarded ratios and P values with an adjusted multivariate Cox proportional hazards regression model, including RTL, age, sex, tumor site, TNM stage, differentiation, Lauren classification, and chemotherapy as covariates. Significant P value was in bold.
a
Only including stage II and stage III GC patients.